Search

Danaher Corp

Closed

SectorHealthcare

202.44 -0.76

Overview

Share price change

24h

Current

Min

201

Max

203.87

Key metrics

By Trading Economics

Income

-159M

870M

Sales

314M

6.3B

P/E

Sector Avg

36.476

57.002

EPS

1.94

Dividend yield

0.7

Profit margin

13.887

Employees

58,000

EBITDA

-364M

1.1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+7.79% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.70%

2.22%

Next Earnings

20 paź 2026

Next Dividend date

30 paź 2026

Next Ex Dividend date

25 wrz 2026

Market Stats

By TradingEconomics

Market Cap

4.8B

147B

Previous open

203.2

Previous close

202.44

News Sentiment

By Acuity

23%

77%

79 / 340 Ranking in Healthcare

Danaher Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 20:06 UTC

Danaher Corp's shares are lower amid concerns over a surprising drop in U.S. retail sales, which fell 0.6% in July against expectations.

13 sie 2026, 23:31 UTC

Danaher Corp shares rose in after-market trading, buoyed by unchanged producer prices in July and easing inflation concerns affecting investor sentiment.

12 sie 2026, 23:46 UTC

Danaher Corp. shares were roughly flat in after-market trading, maintaining a position above its 20-day moving average and near the upper end of its one-month range.

10 sie 2026, 19:42 UTC

Danaher Corp shares are higher today, supported by a broader rise in the Life Sciences Tools & Services sub-sector. The stock remains above its 20-day moving average.

7 sie 2026, 19:36 UTC

News

Danaher Corp's stock is higher today, supported by significant insider transactions. The CFO and Executive Vice President reported acquiring substantial stock options.

6 sie 2026, 20:02 UTC

Shares of Danaher Corp are higher, reflecting broader market gains since Wednesday's close. The stock is near the upper end of its one-month range.

5 sie 2026, 19:51 UTC

Danaher Corp shares are higher today, supported by gains in the Life Sciences Tools & Services sub-sector. The stock has shown notable volatility during the session.

4 sie 2026, 23:01 UTC

Danaher Corp shares are higher in after-market trading, supported by broader market optimism and easing oil prices contributing to favorable inflation expectations.

3 sie 2026, 22:51 UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

31 lip 2026, 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

30 lip 2026, 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

29 lip 2026, 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

28 lip 2026, 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

27 lip 2026, 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

24 lip 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 lip 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 lip 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 lip 2026, 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 lip 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

7.79% upside

12 Months Forecast

Average 219.78 USD  7.79%

High 240 USD

Low 195 USD

Based on 20 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

17

Buy

3

Hold

0

Sell

Sentiment

By Acuity

79 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat